Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam P Dicker

Showing results (241-250 of 286) with videos related to

Pageof 29
Sort By:
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 16, 2016
Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot StudyRonald E Myers, Amy E Leader, Jean Hoffman Censits, et al.
The Lancet. Oncology|December 3, 2014
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1John R Prensner, Shuang Zhao, Nicholas Erho, et al.
Oncology|May 6, 2021
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG CohortMaria Vassilakopoulou, Minhee Won, Walter J Curran, et al.
Cancer|October 4, 2025
Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical careLisa M Gudenkauf, Danielle B Tometich, Aasha I Hoogland, et al.
JCO Clinical Cancer Informatics|August 7, 2020
Provider Engagement in Radiation Oncology Data Science: Workshop ReportAnshu K Jain, Sanjay Aneja, Clifton D Fuller, et al.
BJU International|January 14, 2012
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPeter Grimm, Ignace Billiet, David Bostwick, et al.
Cancer Research Communications|September 20, 2023
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLCJoanne B Weidhaas, Chen Hu, Ritsuko Komaki, et al.
JAMA Oncology|January 10, 2016
Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate CancerJoseph R Evans, Shuang G Zhao, S Laura Chang, et al.
Cancer Research|December 8, 2016
RB Loss Promotes Prostate Cancer MetastasisChellappagounder Thangavel, Ettickan Boopathi, Yi Liu, et al.
Cancer Discovery|September 21, 2012
Dual roles of PARP-1 promote cancer growth and progressionMatthew J Schiewer, Jonathan F Goodwin, Sumin Han, et al.
Pageof 29

Showing results (241-250 of 286) with videos related to

Sort By:
Pageof 29
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 16, 2016
Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot StudyRonald E Myers, Amy E Leader, Jean Hoffman Censits, et al.
The Lancet. Oncology|December 3, 2014
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1John R Prensner, Shuang Zhao, Nicholas Erho, et al.
Oncology|May 6, 2021
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG CohortMaria Vassilakopoulou, Minhee Won, Walter J Curran, et al.
Cancer|October 4, 2025
Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical careLisa M Gudenkauf, Danielle B Tometich, Aasha I Hoogland, et al.
JCO Clinical Cancer Informatics|August 7, 2020
Provider Engagement in Radiation Oncology Data Science: Workshop ReportAnshu K Jain, Sanjay Aneja, Clifton D Fuller, et al.
BJU International|January 14, 2012
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPeter Grimm, Ignace Billiet, David Bostwick, et al.
Cancer Research Communications|September 20, 2023
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLCJoanne B Weidhaas, Chen Hu, Ritsuko Komaki, et al.
JAMA Oncology|January 10, 2016
Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate CancerJoseph R Evans, Shuang G Zhao, S Laura Chang, et al.
Cancer Research|December 8, 2016
RB Loss Promotes Prostate Cancer MetastasisChellappagounder Thangavel, Ettickan Boopathi, Yi Liu, et al.
Cancer Discovery|September 21, 2012
Dual roles of PARP-1 promote cancer growth and progressionMatthew J Schiewer, Jonathan F Goodwin, Sumin Han, et al.
Pageof 29